Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394030 | 0.87 | ATM (0.50) | ATMCA12CA1CA2CA7 | |
| SCHEMBL3348369 | 0.87 | ATM (0.46) | ATMCYP11B2CA12CA1CA2 | |
| SCHEMBL30950268 | 0.81 | CYP2C9 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL844633 | 0.81 | CYP2C9 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15645487 | 0.81 | GPR119 (0.35) | ATMCA12CA1CA2CA9 | |
| SCHEMBL21750020 | 0.80 | ATM (0.44) | ATMCA12CA1CA2CA7 | |
| SCHEMBL20187531 | 0.80 | ATM (0.44) | ATMCYP11B2CA12CA1CA2 | |
| SCHEMBL1770151 | 0.79 | CYP11B2 (0.35) | CYP11B2HTTPOLB | |
| SCHEMBL25190713 | 0.79 | ALDH1A1 (0.49) | ATMCYP11B2CA12CA1CA2 | |
| SCHEMBL21393634 | 0.79 | ATM (0.40) | ATMCYP11B2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-12378240-B2 | Naphthyridinone-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3883567-B1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378240-B2 | Naphthyridinone-aniline compounds for treatment of dermal disorders | TYR, POLR1C, NQO1 | ATM 767/4885CYP11B2 201/4885CA12 4787/4885 |
| US-12202824-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ATM 2679/4885CYP11B2 1784/4885CA12 4595/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ATM 2756/4885CYP11B2 656/4885CA12 3924/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ATM 2679/4885CYP11B2 1784/4885CA12 4595/4885 |
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | ATM 4782/4885CYP11B2 835/4885CA12 2000/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | ATM 2679/4885CYP11B2 1784/4885CA12 4595/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ATM 2679/4885CYP11B2 1784/4885CA12 4595/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | ATM 2199/4885CYP11B2 290/4885CA12 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.